Introduction {#s0070}
============

Dyslipidemia is a disorder of lipid and lipoprotein metabolism, including overproductivity, deficiencies, or other changes in lipid metabolism, which results in abnormal amounts of lipids and lipoproteins in the blood. Dyslipidemia can manifest as an elevation of the total cholesterol (TC), low-density lipoprotein (LDL)--cholesterol, or triglyceride (TG) concentration, or a reduction in the high-density lipoprotein (HDL)--cholesterol concentration in the blood ([@bb0005]). Abnormal lipid levels are one of the essential causes of atherosclerosis and coronary artery disease (CAD) ([@bb0010], [@bb0015]). When lipoproteins in the plasma, and hence in the arterial wall, fall below a certain threshold level, atherogenesis does not occur. However, the absolute value of this threshold varies among individuals and may be very low in subjects with genetic and/or environmental factors that render their arteries highly susceptible to atherogenic processes ([@bb0010], [@bb0015]). Polygenic hypercholesterolemia is characterized by moderate elevations in LDL--cholesterol (3.63--7.77 mmol/L), with serum TG concentrations within the reference range. Like more extreme monogenic diseases, polygenic dyslipidemia is also associated with CAD. Although the main causes of dyslipidemia are high fat intake (particularly saturated fats) and obesity, genetic factors are also considered important, because many individuals vary in their responses to dietary cholesterol. However, there is no clear pattern of inheritance, and a combination of several genetic variants is generally required for this type of hypercholesterolemia ([@bb0020]). Epidemiological studies have established that a reduction in plasma TC reduces the risk of coronary heart disease (CHD) ([@bb0025]), indicating the importance of characterizing the most strongly associated SNPs with the main risk factors for elevated blood lipid levels. This characterization should facilitate the early diagnosis of these risk factors, before the development of CAD symptoms, and the administration of appropriate treatment. Recent genome-wide association studies (GWAS) and other human genetic studies have localized many common SNPs and many loci that influence the levels of different blood lipids, including previously known loci that are potentially involved in lipid metabolism ([@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105]). More than 40 loci have been associated with the levels of one or more blood lipid parameters, and contain many SNPs, but not all of these associations have been confirmed in other populations ([@bb0030], [@bb0040], [@bb0045], [@bb0055], [@bb0060], [@bb0065], [@bb0075], [@bb0080], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145]). Frequent polymorphisms in *ABCA1*, *ANGPTL3*, *APOA1*, *APOA5*, *APOB*, *APOE*, *CELSR2*, *CETP*, *CILP2*, *DOCK7*, *FADS2*, *GALNT2*, *GCKR*, *GPR109A/B*, *GPR81*, *HMGCR*, *KNTC1*, *LCAT*, *LDLR*, *LIPC*, *LIPG*, *LPL*, *MLXIPL*, *NCAN*, *NIACR1*, *NIACR2*, *PCSK9*, *PLTP*, *TOMM40*, *TRIB1*, *TTC39B*, and other loci have been shown to be significantly associated with the blood levels of one or more lipid parameters in many populations ([@bb0030], [@bb0045], [@bb0050], [@bb0060], [@bb0075], [@bb0110], [@bb0120], [@bb0150]). It has been demonstrated that a number of missense mutations at some of these loci can cause different types of monogenic hypercholesterolemia. For example, mutations in the *ABCA1* gene cause familial HDL deficiency, or Tanger disease ([@bb0025]). Similarly, mutations in the *APOA5*, *APOB*, and *APOE* genes cause different types of hyperlipoproteinemias or even familial hypercholesterolemia type B ([@bb0025], [@bb0155], [@bb0160]), but these are rare and usually more severe in their phenotypes. Confirmation of previously identified associations in different ethnic groups can give additional support to the underlying genetic architecture of the associated loci, especially when data from related populations are compared ([@bb0165]). Genetic structure studies of Europeans have shown that populations from Baltic countries (Estonia, Latvia, and Lithuania), together with Poland and the western part of Russia, form rather a homogeneous group, distinct from the rest of the Europe ([@bb0170]). However, there is little information available on the SNPs associated with blood lipid levels in any of these countries.

Here, we report the associations between common SNPs and the plasma levels of different plasma lipids in a relatively large sample of the Latvian population. The main aims of this study were to investigate the associations between the most-informative SNPs from previous GWAS and four blood lipid parameters: TC, HDL--cholesterol, LDL--cholesterol, and TG in the Latvian population and to provide additional information to characterize the genetic factors that influence blood lipid levels.

Materials and methods {#s0005}
=====================

Subjects {#s0010}
--------

We conducted this research using DNA samples from the Genome Database of the Latvian Population (LGDB), which included 18,888 participants in September 2011 when the study sample was selected ([@bb0175]). We selected all individuals from this dataset for whom there was information on all four blood lipid parameters (TC, HDL, LDL, and TG), body mass index (BMI), glucose levels, sex, and age, resulting in 1581 samples. We then filtered out subjects with cardiovascular disease and those undergoing lipid-lowering therapies, resulting finally in 1345 samples. One sample was excluded as an outlier because of an extremely high TG level. A proportion (56.5%) of the samples matched those used in a previous study based on the same genotyping panel ([@bb0180]). The genotypes of those samples were obtained from the database, and the remaining 585 samples were genotyped in this study. Written informed consent was acquired from all LGDB participants. The study protocol was approved by the Central Medical Ethics Committee of Latvia (protocol no 2007 A-7 and 01-29.1/25).

SNP data {#s0015}
--------

We previously created a genotyping panel from GWAS, which contained 144 SNPs that were associated with one or more lipid traits ([@bb0030], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0075], [@bb0080], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0150]). These SNPs occurred in more than 30 loci, including *ABCA1*, *ANGPTL3*, *APOA1*, *APOA5*, *APOB*, *APOE*, *CELSR2*, *CETP*, *CILP2*, *DOCK7*, *FADS2*, *GALNT2*, *GCKR*, *GPR109A/B*, *HMGCR*, *LCAT*, *LDLR*, *LIPC*, *LIPG*, *LPL*, *MLXIPL*, *NCAN*, *NIACR1*, *NIACR1/KNTC1*, *NIACR2*, *NIACR2/GPR81*, *PCSK9*, *PLTP*, *TOMM40*, *TRIB1*, and *TTC39B.* The SNP selection procedure is described in detail in our previous publication ([@bb0180]).

Genotyping and quality control {#s0020}
------------------------------

All 144 SNPs were genotyped with the Illumina BeadXpress System (Illumina GoldenGate Genotyping Assay), according to the manufacturer\'s instructions. The quality control procedure applied to the raw data can be found in our previous article ([@bb0180]). After quality control, the remaining sample consisted of 1273 individuals with 139 genotyped SNPs, with a successful genotyping rate of 99.76%.

Statistical analysis {#s0025}
--------------------

The normal distributions of all quantitative variables were tested with the two most important parameters, the mean value and its standard deviation (SD) ([@bb0185]), and with the Shapiro--Wilk test. None of the lipid levels were normally distributed according to the Shapiro--Wilk test, even after various transformations. Therefore, to assess the influence of the covariates, we used linear regression, applying less-stringent normality criteria: the 68--95--99.7 rule or the three-sigma rule, according to which about 68% of values should fit within an interval of one SD, 95% in two SDs, and 99.7% in three SDs. Among all the variables tested, the TG levels were not normally distributed, so they were log transformed for further statistical analysis. We applied a linear regression analysis with and without the covariates (age, sex, BMI, and glucose levels), and tested epistasis and Hardy--Weinberg equilibrium with the PLINK v2.050 software (<http://pngu.mgh.harvard.edu/purcell/plink/>) ([@bb0190]). The Bonferroni correction was used to calculate the significance level (0.05/139 = 3.5 × 10^− 4^). To calculate the joint effects, all SNPs in genes with more than one nominally associated SNP were divided into haploblocks using HapMap data and Haploview software v4.2 ([@bb0195], [@bb0200]), and one SNP was chosen from each haploblock. The joint effect analyses were performed with the SPSS v13.0 software, using a one-sample *t* test. The association analysis of haplotypes was performed by PLINK toolset. A gene-by-gene interaction analysis was performed with the PLINK v2.050 software and GMDR software Beta 0.9 (<http://sourceforge.net/projects/gmdr/>) ([@bb0205]). Imputation was performed with the IMPUTE2 v2.2.2 software (<https://mathgen.stats.ox.ac.uk/impute/impute_v2.html#home>) ([@bb0210], [@bb0215]) for loci containing more than five SNPs. As reference haplotypes, we used the 1000 Genomes Phase I integrated variant set. The imputation region was set based on the coordinates of the first- and last-tested SNP at each locus. The SNPTEST v2.4.1 software was used to calculate the association between the imputed SNPs and the four lipid parameters (<https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html#Download_and_Compilation>) ([@bb0215]). To accommodate uncertain genotypes, we used the *--method threshold* option, with a threshold value of 0.9. The additive model for association studies was chosen to calculate the *P* values. The Bonferroni threshold was calculated as follows: 0.05/number of our genotyped SNPs (*n* = 139) at all loci. Statistical power was calculated with the Quanto v1.2.4 software ([@bb0220]). The minor allele frequencies (MAFs) of our genotyped SNPs ranged from 0.020 to 0.474. Taking into account this range of MAFs, our study had sufficient power (80%) to detect beta coefficients in the following range for each of the parameters: increased TC, 0.50--0.15; increased LDL--cholesterol, 0.45--0.15; reduced HDL--cholesterol, 0.200; and increased TG, 0.30--0.10.

Results {#s0030}
=======

The clinical characteristics of the study subjects are listed in [Table 1](#t0005){ref-type="table"}.

SNP association tests {#s0035}
---------------------

We performed linear regression analyses for all 139 SNPs with the four blood lipid parameters (TC, HDL, LDL, and logTG). In unadjusted analyses, 26 SNPs from nine loci were associated with TC, 22 SNPs from 10 loci with LDL, 58 SNPs from 13 loci with HDL, and 40 SNPs from 14 loci with logTG at the nominally significant level (*P* \< 0.05). After age, sex, BMI, and glucose levels were added as covariates to the linear regression analysis, 24 SNPs at 11 loci were associated with TC, 23 SNPs at nine loci with LDL, 56 SNPs at 13 loci with HDL, and 40 SNPs at 14 loci with logTG, with the same significance level. Data for the associations of all SNPs are shown in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. In total, 16 SNPs remained significantly associated after the Bonferroni correction was applied ([Table 2](#t0010){ref-type="table"}): 10 SNPs at the *CETP* (cholesteryl ester transfer protein) locus and two SNPs at the *MLXIPL* (MLX-integrating protein like) locus were associated with reduced HDL--cholesterol levels; one SNP at the *TOMM40* (translocase of outer mitochondrial membrane 40) locus was associated with increased LDL--cholesterol; and four SNPs located at the *MLXIPL* locus were associated with increased logTG levels.

Haplotype association test {#s0040}
--------------------------

In order to explore the LD in association with changes in blood lipids detailed haplotype analysis was performed for both genes with more than one significantly associated SNP (*MLXIPL* and *CETP*). We thus selected all SNPs from our panel that were located within or in near proximity of *CETP* and *MLXIPL* gene and assigned them in haploblocks that were generated from the HapMap1/3 data. In total one haploblock was identified in the *MLXIPL locus* but four were found in CETP locus. Acquired haplotype data was further used for haplotype association test. Reconstructed haplotypes that exceeded the frequency of 0.01 and the results of association test are shown in [Table 3](#t0015){ref-type="table"}. More detailed description of *CETP* haplotypes and their genomic localization can be found in our previous paper ([@bb0180]).

Gene--gene interaction test {#s0045}
---------------------------

Pair wise SNP--SNP interactions for all 139 SNPs were analyzed with the *epistasis* option implemented in the PLINK software package to determine whether interactions between two SNPs were associated with lipid levels. We found four pairs of SNPs with *P* values \< 0.0001. One interacting SNP pair was associated with reduced HDL--cholesterol levels (rs1551894 in *HMGCR*, encoding 3-hydroxy-3-methylglutaryl-CoA reductase, interacting with rs6586891 in *LPL*, encoding lipoprotein lipase); two SNP pairs were associated with increased LDL--cholesterol levels (rs4803750 in *TOMM40* interacting with rs157580 in *APOE*, encoding apolipoprotein E; and rs157580 in *APOE* interacting with rs405509 in *TOMM40*); and one pair of SNPs was associated with increased logTG (rs10889353 in *ANGPTL3*, encoding angioprotein-like 3, interacting with rs166358 in *LIPC*, encoding hepatic lipase). We also performed a gene--gene epistasis test with the GMDR software, but this analysis revealed no significant gene--gene interactions.

Imputation {#s0050}
----------

We performed imputation and subsequent association analyses for 11 loci that contained five or more SNPs (*CELSR2*, *APOB*, *HMGCR*, *MLXIPL*, *LPL*, *APOA1/5*, *KNTC1/NIACR1*, *LIPC*, *CETP*, and *TOMM40/APOE*), using the 1000 Genomes Phase I integrated variant set of haplotypes as the reference and the coordinates of the outer SNPs from our 11 loci as the interval boundaries. At four loci, *APOB* (apolipoprotein B), *CETP*, *LPL*, and *TOMM40*, a number of SNPs displayed *P* values lower than the Bonferroni threshold for one or more lipid traits. To illustrate these results, we created Manhattan plots for these four loci (shown in [Fig. 1](#f0005){ref-type="fig"}). The *P* values and *beta* coefficients for the 71 corrected SNPs that were associated with one of the lipid traits after imputation and SNPTEST are shown in [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}. Thus, for *APOB* and *LPL*, only the imputed SNPs reached the appropriate significance level for association with LDL, TC, and HDL. One nucleotide deletion at chr2:21428937 (*APOB* locus) showed the strongest association with LDL cholesterol levels. rs289, located in the sixth intron of the *LPL* gene, displayed the strongest association with HDL--cholesterol. We found a number of imputed SNPs at the *TOMM40* locus that reached the appropriate significance level for their associations with LDL--cholesterol levels, and had lower P values than our genotyped SNPs. The most strongly associated SNP was rs62117206, located in the intron of the *BCL3* gene (B-cell leukemia/lymphoma 3). We found many SNPs with the appropriate significance level at the *CETP* locus for association with HDL--cholesterol; however none of these SNPs had a *P* value lower than that for rs3764261, which was genotyped with our panel. Most of the associated SNPs were found within introns, although some were located in 5′ or 3′ untranslated regions, but none occurred in a coding region.

Joint effect analysis {#s0055}
---------------------

Because the effects of individual SNPs are rather small, we decided to investigate the summary effects of associated SNPs on blood lipid parameters, using the risk allele dosage test and those SNPs that were nominally associated with different blood lipid levels before the Bonferroni correction, each of which represented one haploblock. Sixteen SNPs representing the *ABCA1*, *ANGPTL3*, *APOB*, *APOE*, *DOCK7*, *HMGCR*, *LCAT*, *LIPC*, and *TOMM40* loci were included in case of TC; 24 SNPs representing the *ABCA1*, *APOA1*, *CETP*, *HMGCR*, *NIACR1*, *LCAT*, *LIPC*, *LPL*, *MLXIPL*, *PLTP*, and *TRIB1* loci were included in cases of HDL cholesterol; 15 SNPs representing *ABCA1*, *ANGPTL3*, *APOA1*, *APOB*, *APOE*, *DOCK7*, *HMGCR*, *LCAT*, and *TOMM40* loci were included in case of LDL--cholesterol; and 27 SNPs representing *ABCA1*, *ANGPTL3*, *APOA1*, *APOA5*, *APOB*, *CETP*, *CILP2*, *DOCK7*, *GCKR*, *LIPC*, *LPL*, *MLXIPL*, *NCAN*, and *TOMM40* loci were included in case of logTG. The distribution of risk allele number within each group of lipid parameters analyzed was almost normally distributed and therefore we divided the sample into three equivalent groups based on the range of the risk allele distribution separately for each lipid parameter. We then performed a one-sample *t* test with the SPSS software to calculate the differences between these three groups. We found that the number of risk alleles correlated strongly with the blood lipid levels for all four parameters. The results of this analysis are shown in [Fig. 2](#f0010){ref-type="fig"}. In case of TC the group of individuals with 4--10 risk alleles had a mean TC level 0.53 mmol/L lower than that of the median group, represented by individuals with 11--18 risk alleles (*P* = 1.59E − 44). In the group with 19--26 risk alleles, the mean TC level was 0.40 mmol/L higher (*P* = 4.18E − 97) than that in the median group. The mean HDL--cholesterol level was 0.24 mmol/L higher (*P* = 1.59E − 44) in the group with 13--21 risk alleles and 0.18 mmol/L lower (*P* = 7.51E − 241) in the group with 31 − 40 risk alleles compared to the value for the median group (22--30 risk alleles). The mean LDL--cholesterol level was 0.56 mmol/L lower (*P* = 1.36E − 22) in the group with two to nine risk alleles and 0.51 mmol/L higher (*P* = 7.91E − 140) in the group with 10--17 risk alleles compared to the value in the median group (10--17 risk alleles). The mean logTG value was 0.07 log mmol/L lower (*P* = 1.06E − 31) in the group with 13--21 risk alleles and 0.09 log mmol/L higher (*P* = 1.76E − 34) in the group with 30--39 risk alleles compared to the median group (22--29 risk alleles).

Discussion {#s0060}
==========

The aim of this study was to identify associations between 144 SNPs selected from published GWAS and blood lipid levels in the Latvian population. This is the first report in which many genetic loci, involved in a number of lipid-related metabolic pathways, were simultaneously studied in a relatively large group representing the Latvian population (420 males, 853 females; for detailed data, see [Table 1](#t0005){ref-type="table"}). Our study has convincingly identified associations between 16 of the 139 most strongly associated SNPs and one or more blood lipid parameters.

In our previous case--control study, we reported strong associations between 10 SNPs in *CETP* and reduced HDL--cholesterol ([@bb0180]). In this study, we confirmed this strong evidence for this association between the *CETP* gene and HDL--cholesterol levels and discovered the new association of two SNPs at the *MLXIPL* locus ([Table 2](#t0010){ref-type="table"}), using quantitative analyses. Moreover, haplotype analyses also confirmed the associations demonstrated in our previous study ([@bb0180]). These results also agree well with those of other studies around the world ([@bb0045], [@bb0055], [@bb0060], [@bb0075], [@bb0080], [@bb0105], [@bb0110], [@bb0120], [@bb0150], [@bb0225], [@bb0230]) and are supported by the well-known function of CETP in lipid metabolism. CETP promotes the transfer of cholesteryl esters from HDL particles to apolipoprotein-B-containing particles in exchange for TG, allowing the receptor-mediated uptake of cholesterol esters by the liver and reducing HDL--cholesterol levels ([@bb0010]). In contrast, CETP deficiency increases HDL--cholesterol levels. Supporting the association between SNPs in the *MLXIPL* locus and HDL--cholesterol, several reports have linked *MLXIPL* and HDL--cholesterol. However, their relationship within the lipid metabolic pathways is not as direct as that of the SNP--*CETP* association. The protein encoded by the *MLXIPL* gene is a helix--loop--helix leucine zipper transcription factor, which forms a heterodimer with MLX to bind DNA ([@bb0235]). This transcription factor complex is activated by high glucose and inhibited by cyclic adenosine monophosphate (cAMP) ([@bb0240]), and can repress E-box-dependent transcription ([@bb0235]) or the carbohydrate response element motifs in the promoters of lipogenic enzymes. In adipose tissues, MLXIPL is a major determinant of adipose tissue fatty-acid synthesis and systemic insulin sensitivity ([@bb0245]). Therefore, it is plausible that changes in MLXIPL expression indirectly influence HDL--cholesterol levels through various metabolic pathways.

We also found strong associations between four SNPs at the *MLXIPL* locus and increased logTG ([Table 2](#t0010){ref-type="table"}). Because MLXIPL is a transcription factor that influences fatty-acid synthesis in adipose tissue, it is plausible that SNPs in this gene indirectly affect TG levels. We also found that a SNP in the *TOMM40* locus is associated with increased LDL--cholesterol levels ([Table 2](#t0010){ref-type="table"}). More precisely, this SNP is located in the first intron of the *BCL3* gene ([Fig. 1](#f0005){ref-type="fig"} TOMM40 locus). The protein encoded by the *BCL3* gene is an inhibitor of subunit two of nuclear factor kappa-B (NF-κB) ([@bb0250], [@bb0255]). Because interactions between BCL3 and NF-κB have not yet been linked to lipid metabolism, we think that this SNP might be in linkage disequilibrium (LD) with functional SNPs in one of the genes encoding various apolipoproteins located downstream from the *TOMM40* gene. For example, mutations in the *APOE* gene (located immediately downstream from *TOMM40*) can cause hyperlipoproteinemia type III ([@bb0260]). Alternatively, the associated SNPs may be located within upstream regulatory elements of these apolipoprotein genes because the distance between the *TOMM40* gene and, for example, the *APOE* gene is rather large (2.1 Mbp), arguing against a simple LD-based explanation.

Since the number of associated SNPs was found in *CETP* and *MLXIPL* gene, we estimated the association of individual haplotypes with all lipid levels. First it should be noted that in case of *CETP* the results of HDL associations corresponded exactly to our previous findings ([@bb0180]). Most of the associated SNPs fall in second and third haploblock ([Table 3](#t0015){ref-type="table"}). These haploblocks cover the region starting from \~ 2 kb upstream *CETP* gene, promoter region and include first \~ 10 kb of *CETP* gene. Interestingly, the strongest association was observed for two protective haplotypes with increased HDL levels: haplotype 2.1 from second haploblock and 3.1 from the third haploblock. For second haploblock it is clear that effect is explained by the presence of risk alleles from two SNPs rs173539 and rs3764261 that are both in strong LD with each other (*R*^2^ = 0.94). In case of third haploblock T allele of rs9939224 from the second intron of CETP gene is present only in two "risk" haplotypes and may be linked to the increased expression or functionality of CETP, thus decreasing the HDL-C levels as suggested by our previous observations ([@bb0180]). The effect of "protective" haplotype may be explained by the presence of rs1800775 A allele that has been linked to changes in binding site Sp1/Sp3 in functional studies ([@bb0265], [@bb0270]). In case of *MLXIPL* one protective haplotype was identified that was associated with increased HDL and decreased logTG levels and one risk haplotype associated with decreased HDL. Due to strong LD it is however less clear which of the tested SNPs may be responsible for these effects.

An epistasis analysis was performed to test whether there was any gene--gene interactions among the SNPs examined in this study. We found four pairs of SNPs that showed probable interactions in their associations with blood lipid parameters. Two pairs of SNPs, located again in the *TOMM40* and *APOE* genes, showed functional or LD-based interactions that affected LDL--cholesterol levels. Another two interactions were associated with HDL--cholesterol (*HMGCR* and *LPL*) or logTG levels (*ANGPTL3* and *LIPC*). The *HMGCR* gene encodes 3-hydroxy-3-methylglutaryl-CoA reductase, which catalyzes the crucial step in cholesterol biosynthesis ([@bb0010]). In contrast, the *LPL* gene encodes lipoprotein lipase, which hydrolyzes TGs derived from blood lipid particles. These are taken up into cells as fatty acids and are stored or delivered to the cholesterol or TG synthetic pathways ([@bb0010]). This interaction thus is supported by the known gene functions. *ANGPTL3* encodes angiopoietin-like 3 protein, which belongs to the specific vascular endothelium growth factor protein family ([@bb0275]), and homozygous or compound heterozygous mutations in *ANGPTL3* cause familial hypobetalipoproteinemia type II ([@bb0280]). The *LIPC* gene encodes hepatic lipase, which is synthesized in the liver and acts in the uptake of lipoproteins and cholesteryl esters by hepatocytes, thus directly influencing plasma lipid levels ([@bb0285]). It is not known how these two proteins interact to influence lipid metabolism, but such interactions cannot be excluded. However, it should be noted that the majority of genes selected for this study have well-established functions in lipid metabolism. Therefore, all attempts to explain these interactions statistically, based on the relationships of these protein functions, are highly biased, and in all cases, further investigation is required in large well-characterized cohorts. Unfortunately, these findings were not supported by the GMDR software, perhaps because more-specific algorithms are used in GHMDR, taking into account, for example, covariates, "course of dimensionality", and other criteria that are not included in the PLINK toolset and which therefore better exclude false positive results ([@bb0290]).

For a more detailed analysis and to find other strongly associated SNPs at our test loci, we performed imputation for 11 loci that contained five or more SNPs (*CELSR2*, *APOB*, *HMGCR*, *MLXIPL*, *LPL, APOA1/5*, *KNTC1/NIACR1*, *LIPC*, *CETP*, and *TOMM40/APOE*). We found many imputed SNPs in the *CETP* gene that were associated with changes in HDL--cholesterol levels; although none of these associations was stronger than those of the originally genotyped SNPs ([Fig. 1](#f0005){ref-type="fig"} *CETP* locus). These results again agree well with those of our previous study, in that *CETP* is the strongest and most common genetic factor to influence HDL--cholesterol levels in the Latvian population. Imputed SNPs at another three loci, *APOB*, *LPL*, and *TOMM40*, were significantly associated with one or more lipid trait ([Fig. 1](#f0005){ref-type="fig"}). All these SNPs were located in noncoding regions and many of them have already been associated with disease phenotypes, including CAD, myocardial infarction, and atherosclerosis. The *APOB* and *LPL* genes are known to be directly involved in lipid metabolism, and a number of functional mutations in these genes have already been reported to cause different types of monogenic familial hypercholesterolemia (<http://www.hgmd.org/>). Therefore, it is likely that common variants with smaller effects may play roles in milder forms of dyslipidemia. It is also possible that our cohort contained a number of patients with undiagnosed monogenic hypercholesterolemia. This may have influenced the association results either because of the LD between these mutations and the markers used in our study or simply by adding a stronger genetic modifier. A number of imputed SNPs at the *TOMM40* locus reached the appropriate significance level in their associations with LDL--cholesterol levels. Again, the role of TOMM40 in the regulation of LDL metabolism is unclear (see discussion above).

To achieve our aim, we performed an allele dosage association test with nominally associated SNPs, each representing one haploblock, for all four blood lipid parameters to calculate the influence of the number of risk alleles on lipid levels. We divided our sample in three equivalent groups based on the number of risk alleles. There was a strong correlation between the number of risk alleles and the plasma lipid levels for all four lipid parameters ([Fig. 2](#f0010){ref-type="fig"}). Therefore, it is possible that the discovery and inclusion of additional lipid-influencing SNPs in similar analyses will lead to the development of prognostic tests for dyslipidemia and the prescription of appropriate drugs.

Conclusions {#s0065}
===========

The results of this study confirm that of all the genes included in the analysis, *CETP, MLXIPL*, and *TOMM40* are the genetic factors that most strongly influence the plasma lipid levels in our study population. We have also shown that these risk alleles have strong cumulative effects on all lipid parameters. It should be noted that this is the first replication study of a relatively large sample population from the Baltic States and Eastern Europe.

Abbreviations {#s0075}
=============

CADcoronary artery diseaseTCtotal cholesterolSNPsingle-nucleotide polymorphismLDLlow-density lipoproteinHDLhigh-density lipoproteinTGtriglycerideBMIbody mass indexMAFminor allele frequencyCHRchromosomeMAminor alleleGWASgenome-wide association studiescAMPcyclic adenosine monophosphateLDlinkage disequilibriumSDstandard deviation
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![Manhattan plots of imputed SNPs and the four lipid parameters for the four most strongly associated loci.\
These data plots show the *P* values for SNPs associated with all four lipid traits: filled symbols indicate *P* values of the originally genotyped SNPs in our study; empty symbols indicate *P* values of the imputed SNPs; black arrows indicate genes located at the studied loci and their directions; red lines indicate the Bonferroni threshold of 0.05/139 = 3.60E − 04.](gr1){#f0005}

![Joint effect analyses for all blood lipid parameters.\
Analysis of the joint risk allele effects on A, total cholesterol; B, high-density lipoprotein--cholesterol; C, low-density lipoprotein--cholesterol, and D, log triglycerides. The Y axis represents the level of the corresponding blood lipid (in mmol/L); the X axis represents three equal groups, based on the number of risk alleles; black squares indicate the mean values for the lipids in each group, with the 95% confidence interval of the mean difference. The dotted line indicates the linear correlation between the groups and the *R*^2^ value is shown for each lipid trait.](gr2){#f0010}

###### 

Sample characteristics.

  Variable                            
  ----------------------------------- -----------------------------
  *n*                                 1273
  SNPs genotyped                      139
  Genotyping rate, %                  99.76%
  Mean age, years ± SD (min--max)     52.05 ± 13.73 (18--82)
  Female gender, %                    67.0%
  TC-level, mmol/L ± SD (min--max)    5.78 ± 1.24 (1.95--11.7)
  TC, median (Q1; Q3)                 5.70 (4.91; 6.55)
  LDL-level, mmol/L ± SD (min--max)   3.57 ± 1.07 (0.72--8.4)
  LDL, median (Q1; Q3)                3.48 (2.81; 4.24)
  HDL-level, mmol/L ± SD (min--max)   1.59 ± 0.44 (0.33--3.52)
  HDL, median (Q1; Q3)                1.53 (1.28; 1.87)
  TG-level, mmol/L ± SD (min--max)    1.40 ± 0.75 (0.29--5.87)
  TG, median (Q1; Q3)                 1.22 (0.89; 1.74)
  BMI, kg/m^2^ ± SD (min--max)        27.02 ± 5.14 (15.64--59.73)

SD, standard deviation; min, minimum value of variable; max, maximum value of variable; Q1, first quartile of the interquartile range; Q3, third quartile of the interquartile range; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; BMI, body mass index.

###### 

SNPs significantly associated with lipid parameters.

![](t1)

SNPs with *P* values \< 0.05 are marked in bold; SNPs with P values \< 0.05 after Bonferroni correction are black highlighted with white letters. All calculations were made with a linear regression analysis with covariates (age, sex, BMI, and glucose levels). CHR, chromosome; SNP, single-nucleotide polymorphism; MA, minor allele; MAF, minor allele frequency; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

###### 

Haplotypes in CETP and MLXIPL genes associated with blood lipid levels.

![](t2)

FRQ, frequency of haplotypes; TC, total cholesterol; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol, logTG, logarithmic value of triglyceride level; ID, haplotype identification number (first digit---number of haploblock studied; second digit---number of individual haplotype); first haploblock of CETP gene consists of rs2241770 and rs16962767; second haploblock of CETP gene consists of rs12448528, rs173539, rs12708967 and rs3764261; third haploblock of CETP gene consists of rs1800775, rs711752, rs708272, rs1864163, rs9929488, rs7203984, rs9939224, rs7205804 and rs11076175; fourth haploblock of CETP gene consists of rs5880 and rs1800777; first haploblock of MLXIPL gene consists of rs2240466, rs1178979, rs714052, rs17145738, rs2286276 and rs11974409; haplotypes considered as "protective" are highlighted in grey; haplotypes considered as "risk" are highlighted in black with white letters; *P*-values lower than 0.05 are highlighted in black with white letters.
